title: Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
authors.forename: C
authors.initials: C
authors.lastname: Karlsson
authors.forename: S
authors.initials: S
authors.lastname: Norin
authors.forename: E
authors.initials: E
authors.lastname: Kimby
authors.forename: B
authors.initials: B
authors.lastname: Sander
authors.forename: A
authors.initials: A
authors.lastname: Porwit Macdonald
authors.forename: B
authors.initials: B
authors.lastname: Nilsson
authors.forename: E
authors.initials: E
authors.lastname: Johansson
authors.forename: H
authors.initials: H
authors.lastname: Mellstedt
authors.forename: J
authors.initials: J
authors.lastname: Lundin
authors.forename: A
authors.initials: A
authors.lastname: Osterborg
mesh_terms: D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007239:Infections / Q000209:etiology*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab